SAPL stock snapshot.
Sanofi-Aventis Pakistan Limited price, fundamentals, financial report trends, and one-year performance against the KSE-100.
SAPL vs. KSE-100
Latest report-period signals.
Parsed conservatively from PSX financial report PDFs. Card values are latest report-period figures, so quarterly filings show quarterly values rather than annualized totals.
Report metrics extracted
| Stock | Trailing P/E | Price / book | ROE | Net margin | Debt / equity | Market cap | Day change |
|---|---|---|---|---|---|---|---|
SAPL Sanofi-Aventis Pakistan Limited | n/a | n/a | n/a | n/a | n/a | PKR 8.4bn | 0.00% |
| GLAXO →GlaxoSmithKline Pakistan Limited | 10.98 | 3.03 | 29.77% | 15.21% | 48.79% | PKR 110.1bn | -0.21% |
| ABOT →Abbott Laboratories (Pakistan) Limited | 11.27 | 2.67 | 25.19% | 10.57% | 48.93% | PKR 89.8bn | +0.36% |
| HALEON →Haleon Pakistan Limited | 13.82 | 6.05 | 43.07% | 14.78% | 105.49% | PKR 88.1bn | -0.15% |
| AGP →AGP Limited | 22.65 | 3.97 | 18.27% | 11.49% | 62.09% | PKR 53.5bn | -0.20% |
Sanofi-Aventis Pakistan Limited
The Company was incorporated in Pakistan in 1967 as a Public Limited Company under Companies Act, 1913 (now Companies Act, 2017). The Company is a subsidiary of Sanofi Foreign Participations B.V. registered in Netherlands. The ultimate parent of the Company is Sanofi S.A., France. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products.
Turn SAPL from a quote into a decision trail.
PSX Clarity connects live prices, filings, dividends, and report metrics to the portfolio you actually follow.